• Something wrong with this record ?

Process performance and product quality in an integrated continuous antibody production process

DJ. Karst, F. Steinebach, M. Soos, M. Morbidelli,

. 2017 ; 114 (2) : 298-307. [pub] 20160817

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

Continuous manufacturing is currently being seriously considered in the biopharmaceutical industry as the possible new paradigm for producing therapeutic proteins, due to production cost and product quality related benefits. In this study, a monoclonal antibody producing CHO cell line was cultured in perfusion mode and connected to a continuous affinity capture step. The reliable and stable integration of the two systems was enabled by suitable control loops, regulating the continuous volumetric flow and adapting the operating conditions of the capture process. For the latter, an at-line HPLC measurement of the harvest concentration subsequent to the bioreactor was combined with a mechanistic model of the capture chromatographic unit. Thereby, optimal buffer consumption and productivity throughout the process was realized while always maintaining a yield above the target value of 99%. Stable operation was achieved at three consecutive viable cell density set points (20, 60, and 40 × 106 cells/mL), together with consistent product quality in terms of aggregates, fragments, charge isoforms, and N-linked glycosylation. In addition, different values for these product quality attributes such as N-linked glycosylation, charge variants, and aggregate content were measured at the different steady states. As expected, the amount of released DNA and HCP was significantly reduced by the capture step for all considered upstream operating conditions. This study is exemplary for the potential of enhancing product quality control and modulation by integrated continuous manufacturing. Biotechnol. Bioeng. 2017;114: 298-307. © 2016 Wiley Periodicals, Inc.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18017114
003      
CZ-PrNML
005      
20180516110505.0
007      
ta
008      
180515s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/bit.26069 $2 doi
035    __
$a (PubMed)27497430
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Karst, Daniel J $u Department of Chemistry and Applied Biosciences, Institute for Chemical and Bioengineering, ETH Zurich, Vladimir-Prelog-Weg 1, Zurich CH-8093, Switzerland.
245    10
$a Process performance and product quality in an integrated continuous antibody production process / $c DJ. Karst, F. Steinebach, M. Soos, M. Morbidelli,
520    9_
$a Continuous manufacturing is currently being seriously considered in the biopharmaceutical industry as the possible new paradigm for producing therapeutic proteins, due to production cost and product quality related benefits. In this study, a monoclonal antibody producing CHO cell line was cultured in perfusion mode and connected to a continuous affinity capture step. The reliable and stable integration of the two systems was enabled by suitable control loops, regulating the continuous volumetric flow and adapting the operating conditions of the capture process. For the latter, an at-line HPLC measurement of the harvest concentration subsequent to the bioreactor was combined with a mechanistic model of the capture chromatographic unit. Thereby, optimal buffer consumption and productivity throughout the process was realized while always maintaining a yield above the target value of 99%. Stable operation was achieved at three consecutive viable cell density set points (20, 60, and 40 × 106 cells/mL), together with consistent product quality in terms of aggregates, fragments, charge isoforms, and N-linked glycosylation. In addition, different values for these product quality attributes such as N-linked glycosylation, charge variants, and aggregate content were measured at the different steady states. As expected, the amount of released DNA and HCP was significantly reduced by the capture step for all considered upstream operating conditions. This study is exemplary for the potential of enhancing product quality control and modulation by integrated continuous manufacturing. Biotechnol. Bioeng. 2017;114: 298-307. © 2016 Wiley Periodicals, Inc.
650    _2
$a zvířata $7 D000818
650    _2
$a monoklonální protilátky $x analýza $x izolace a purifikace $x metabolismus $7 D000911
650    _2
$a bioreaktory $7 D019149
650    _2
$a CHO buňky $7 D016466
650    _2
$a buněčné kultury $x metody $7 D018929
650    _2
$a křečci praví $7 D006224
650    _2
$a Cricetulus $7 D003412
650    _2
$a perfuze $x metody $7 D010477
650    _2
$a proteinové agregáty $7 D066329
650    _2
$a protein - isoformy $x chemie $7 D020033
650    _2
$a rekombinantní proteiny $x analýza $x izolace a purifikace $x metabolismus $x normy $7 D011994
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Steinebach, Fabian $u Department of Chemistry and Applied Biosciences, Institute for Chemical and Bioengineering, ETH Zurich, Vladimir-Prelog-Weg 1, Zurich CH-8093, Switzerland.
700    1_
$a Soos, Miroslav $u Department of Chemistry and Applied Biosciences, Institute for Chemical and Bioengineering, ETH Zurich, Vladimir-Prelog-Weg 1, Zurich CH-8093, Switzerland. Department of Chemical Engineering, University of Chemistry and Technology, Technicka 5, Prague 166 28, Czech Republic.
700    1_
$a Morbidelli, Massimo $u Department of Chemistry and Applied Biosciences, Institute for Chemical and Bioengineering, ETH Zurich, Vladimir-Prelog-Weg 1, Zurich CH-8093, Switzerland.
773    0_
$w MED00000795 $t Biotechnology and bioengineering $x 1097-0290 $g Roč. 114, č. 2 (2017), s. 298-307
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27497430 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180515 $b ABA008
991    __
$a 20180516110640 $b ABA008
999    __
$a ok $b bmc $g 1300738 $s 1013954
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 114 $c 2 $d 298-307 $e 20160817 $i 1097-0290 $m Biotechnology and bioengineering $n Biotechnol Bioeng $x MED00000795
LZP    __
$a Pubmed-20180515

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...